Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kennelly

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Urology|January 8, 2013
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysisMichael Kennelly, Roger Dmochowski, Karen Ethans, et al.
The Journal of Spinal Cord Medicine|August 29, 2012
International standards to document remaining autonomic function after spinal cord injuryAndrei Krassioukov, Fin Biering-Sørensen, William Donovan, et al.
Advances in Urology|May 9, 2019
Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract InfectionsMichael Kennelly, Nikesh Thiruchelvam, Márcio Augusto Averbeck, et al.
Current Medical Research and Opinion|February 21, 2018
Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settingsMichael Kennelly, Lonny Green, Nancy Alvandi, et al.
Journal of Neurotrauma|November 8, 2017
Intermittent Catheterization: The Devil Is in the DetailsKathleen Christison, Matthias Walter, Jean-Jacques J M Wyndaele, et al.
Neurourology and Urodynamics|November 27, 2015
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension studyMichael Kennelly, Roger Dmochowski, Heinrich Schulte-Baukloh, et al.
British Journal of Nursing (Mark Allen Publishing)|October 13, 2023
Risk factors for urinary tract infections associated with lower quality of life among intermittent catheter usersMarcio Augusto Averbeck, Michael Kennelly, Nikesh Thiruchelvam, et al.
International Journal of Clinical Practice|June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR TrialDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Spinal Cord Medicine|March 3, 2004
Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trialJang Hwan Kim, David A Rivas, Patrick J Shenot, et al.
Spine|April 2, 2008
Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injuryFrancois Giuliano, Eusebio Rubio-Aurioles, Michael Kennelly, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Urology|January 8, 2013
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysisMichael Kennelly, Roger Dmochowski, Karen Ethans, et al.
The Journal of Spinal Cord Medicine|August 29, 2012
International standards to document remaining autonomic function after spinal cord injuryAndrei Krassioukov, Fin Biering-Sørensen, William Donovan, et al.
Advances in Urology|May 9, 2019
Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract InfectionsMichael Kennelly, Nikesh Thiruchelvam, Márcio Augusto Averbeck, et al.
Current Medical Research and Opinion|February 21, 2018
Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settingsMichael Kennelly, Lonny Green, Nancy Alvandi, et al.
Journal of Neurotrauma|November 8, 2017
Intermittent Catheterization: The Devil Is in the DetailsKathleen Christison, Matthias Walter, Jean-Jacques J M Wyndaele, et al.
Neurourology and Urodynamics|November 27, 2015
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension studyMichael Kennelly, Roger Dmochowski, Heinrich Schulte-Baukloh, et al.
British Journal of Nursing (Mark Allen Publishing)|October 13, 2023
Risk factors for urinary tract infections associated with lower quality of life among intermittent catheter usersMarcio Augusto Averbeck, Michael Kennelly, Nikesh Thiruchelvam, et al.
International Journal of Clinical Practice|June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR TrialDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Spinal Cord Medicine|March 3, 2004
Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trialJang Hwan Kim, David A Rivas, Patrick J Shenot, et al.
Spine|April 2, 2008
Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injuryFrancois Giuliano, Eusebio Rubio-Aurioles, Michael Kennelly, et al.
Pageof 4